Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Altimmune Inc

Healthcare US ALT

2.87USD
-0.03(1.03%)

Last update at 2026-06-03T20:23:00Z

Day Range

2.842.95
LowHigh

52 Week Range

2.877.73
LowHigh

Fundamentals

  • Previous Close 2.90
  • Market Cap463.17M
  • Volume3030106
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-94.37700M
  • Revenue TTM0.04M
  • Revenue Per Share TTM-
  • Gross Profit TTM -66.39100M
  • Diluted EPS TTM-1.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -88.77400M -95.05900M -88.44700M -84.91000M -97.09082M
Minority interest - - - - -
Net income -88.09300M -95.05900M -88.44700M -84.71300M -96.17131M
Selling general administrative 28.10M 20.97M 18.14M 17.13M 15.41M
Selling and marketing expenses - - - - -
Gross profit -0.07100M 0.02M 0.43M -0.06800M 4.41M
Reconciled depreciation 0.11M 0.24M 0.48M -0.20500M 0.55M
Ebit -94.60100M -95.05000M -88.41200M -87.74000M -96.91404M
Ebitda -94.48900M -94.81200M -87.93500M -84.90200M -85.71517M
Depreciation and amortization 0.11M 0.24M 0.48M 2.84M 11.20M
Non operating income net other - - - - -0.17113M
Operating income -94.48900M -103.17200M -95.92900M -87.74000M -96.91404M
Other operating expenses 94.53M 103.19M 96.36M 87.67M 89.95M
Interest expense 1.64M 0.00900M 0.04M 0.00800M 0.00566M
Tax provision -0.68100M 0.00000M 0.00000M -0.19700M 0.00000M
Interest income 7.54M 8.07M 7.35M 2.87M 0.20M
Net interest income 5.91M 8.06M 7.32M 2.86M 0.20M
Extraordinary items - - - - -
Non recurring - - - - 11.37M
Other items - - - - -
Income tax expense -0.68100M - 0.31M -0.19700M -0.91951M
Total revenue 0.04M 0.02M 0.43M -0.06800M 4.41M
Total operating expenses 94.53M 103.19M 96.36M 87.67M 89.95M
Cost of revenue 0.11M 0.24M 0.48M 0.07M -
Total other income expense net 5.71M 8.11M 7.48M 2.83M -0.17678M
Discontinued operations - - - - -
Net income from continuing ops -88.09300M -95.05900M -88.44700M -84.71300M -97.09082M
Net income applicable to common shares - - - -84.71300M -97.09082M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 279.93M 139.31M 210.64M 206.93M 218.86M
Intangible assets - - - 12.42M 12.42M
Earning assets - - - - -
Other current assets 3.00M 2.25M 6.82M 5.36M 13396.50M
Total liab 55.04M 15.80M 16.54M 21.64M 19.73M
Total stockholder equity 224.89M 123.51M 194.10M 185.29M 199.13M
Deferred long term liab - - - - -
Other current liab 12.02M 9.98M 9.58M 11.80M 6.09M
Common stock 0.01M 0.00700M 0.00700M 0.00500M 0.00409M
Capital stock 0.01M 0.00700M 0.00700M 0.00500M 0.00409M
Retained earnings -649.48300M -561.39000M -466.33100M -377.88400M -293.17142M
Other liab - - - 3.91M 0.33M
Good will - - - - -
Other assets - - 0.00000M 0.02M 0.07M
Cash 43.76M 36.93M 135.16M 111.10M 190.30M
Cash and equivalents - - - - -
Total current liabilities 15.00M 10.47M 12.14M 17.05M 18.28M
Current deferred revenue - - 0.00000M - 9.74M
Net debt -8.07200M -35.24500M -134.48700M -109.97300M -188.76566M
Short term debt 0.26M 0.28M 0.50M 0.45M 0.41M
Short long term debt - - - - -
Short long term debt total 35.69M 1.68M 0.67M 1.12M 1.54M
Other stockholder equity 879.29M 689.86M 665.43M 568.40M 497.34M
Property plant equipment - - - 1.68M 1.45M
Total current assets 278.19M 137.25M 209.53M 192.81M 204.13M
Long term investments - - - - -
Net tangible assets - - - 172.87M 186.72M
Short term investments 229.70M 94.97M 62.70M 73.78M 0.00000M
Net receivables 1.74M 3.12M 4.85M 2.54M 5.84M
Long term debt 34.29M - - - 1.45M
Inventory - - - 0.03M -13388.51614M
Accounts payable 2.72M 0.21M 2.07M 4.80M 2.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.92800M -4.97300M -5.00400M -5.22700M -5.04016M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00409M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -293.17142M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.43M 1.64M 0.10M 0.61M 0.87M
Deferred long term asset charges - - - - -
Non current assets total 1.74M 2.05M 1.11M 14.12M 14.74M
Capital lease obligations 1.40M 1.68M 0.67M 1.12M 1.54M
Long term debt total - - - - 1.45M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -132.46200M -28.38600M 13.73M -73.39900M 99.83M
Change to liabilities - - - 2.77M -0.87717M
Total cashflows from investing activities -132.47300M -28.38600M 13.73M -73.39900M 87.52M
Net borrowings 35.00M 0.00000M - - -
Total cash from financing activities 206.84M 10.04M 86.11M 56.78M 65.10M
Change to operating activities - - - 8.04M -8.20725M
Net income -88.09300M -95.05900M -88.44700M -84.71300M -97.09082M
Change in cash 6.83M -98.19000M 24.03M -79.20400M 74.38M
Begin period cash flow 36.97M 135.16M 111.13M 190.34M 115.95M
End period cash flow 43.80M 36.97M 135.16M 111.13M 190.33M
Total cash from operating activities -67.53500M -79.84800M -75.81000M -62.58600M -78.23794M
Issuance of capital stock 173.73M 9.99M 86.82M 56.35M 65.04M
Depreciation 0.11M 0.24M 0.48M -0.20500M 0.55M
Other cashflows from investing activities - - - - -0.19454M
Dividends paid - - - - -
Change to inventory - - 0.00000M - -
Change to account receivables 2.06M 1.74M -2.31200M 0.26M 4.18M
Sale purchase of stock 0.29M 0.30M 0.21M 0.18M 224.47M
Other cashflows from financing activities -0.70900M 0.05M -0.49600M 0.25M -224.41407M
Change to netincome - - - 8.22M 18.55M
Capital expenditures 0.01M 0.00000M 0.05M 0.13M 12.31M
Change receivables - - - - 4.18M
Cash flows other operating - - - - -3.55472M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 74.38M
Change in working capital 6.75M 4.48M -8.27400M 14.11M -0.25053M
Stock based compensation 16.08M 14.39M 10.64M 8.10M 5.52M
Other non cash items -1.70100M -3.89800M 9.79M 0.12M 0.70M
Free cash flow -67.54600M -79.84800M -75.85700M -62.71200M -90.54959M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALT
Altimmune Inc		 -0.03 1.03% 2.87 - 8.18 11296.94 2.06 5497.72 11.93
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune Inc

910 Clopper Road, Gaithersburg, MD, United States, 20878

Key Executives

Name Title Year Born
Dr. Vipin K. Garg Ph.D. Pres, CEO & Director 1958
Mr. Richard I. Eisenstadt M.B.A. Chief Financial Officer 1958
Dr. M. Scot Roberts Ph.D. Chief Scientific Officer 1959
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS Chief Medical Officer 1953
Mr. Bertrand Georges Ph.D. Chief Technology Officer NA
Mr. Tony Blandin B.S. VP of Quality & Compliance Management NA
Mr. José Ochoa Chief Bus. Officer NA
Mr. Kent A. Tapper BSEE Corp. Controller 1957
Dr. Vipin K. Garg Ph.D. President, CEO & Director 1958
Mr. Raymond M. Jordt M.B.A. Chief Business Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.